Hemolytic-uremic syndrome secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) No edit summary |
|||
| (3 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{HUS}} | {{HUS}} | ||
{{CMG}}; {{AE}} | {{CMG}} {{shyam}}; {{AE}} {{S.G.}} | ||
==Overview== | ==Overview== | ||
[[Hydration]] and supportive [[therapy]] can restrict [[complications]]. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
Effective measures for the secondary prevention of HUS include:<ref name="Grisaru2014">{{cite journal|last1=Grisaru|first1=Silviu|title=Management of hemolytic-uremic syndrome in children|journal=International Journal of Nephrology and Renovascular Disease|year=2014|pages=231|issn=1178-7058|doi=10.2147/IJNRD.S41837}}</ref><ref>{{Cite journal | Effective measures for the [[Secondary Prevention'''|secondary prevention]] of HUS include:<ref name="Grisaru2014">{{cite journal|last1=Grisaru|first1=Silviu|title=Management of hemolytic-uremic syndrome in children|journal=International Journal of Nephrology and Renovascular Disease|year=2014|pages=231|issn=1178-7058|doi=10.2147/IJNRD.S41837}}</ref><ref>{{Cite journal | ||
| author = [[Hoon Young Choi]] & [[Sung Kyu Ha]] | | author = [[Hoon Young Choi]] & [[Sung Kyu Ha]] | ||
| title = Potassium balances in maintenance hemodialysis | | title = Potassium balances in maintenance hemodialysis | ||
| Line 24: | Line 20: | ||
}}</ref><ref>{{cite journal|doi=10.1007/s00467-018-4025-0 Share on FacebookShare on TwitterShare on Google+}}</ref> | }}</ref><ref>{{cite journal|doi=10.1007/s00467-018-4025-0 Share on FacebookShare on TwitterShare on Google+}}</ref> | ||
*Supportive therapy and hydration | *Supportive [[therapy]] and [[hydration]] | ||
* | *Close observation for worsening clinical status | ||
*Use eculizumab in | *Use of [[eculizumab]] in atypical HUS | ||
*Avoidance of nephrotoxic medications | |||
==References== | ==References== | ||
Latest revision as of 02:40, 21 December 2018
|
Hemolytic-uremic syndrome Microchapters |
|
Differentiating Hemolytic-uremic syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hemolytic-uremic syndrome secondary prevention On the Web |
|
American Roentgen Ray Society Images of Hemolytic-uremic syndrome secondary prevention |
|
Risk calculators and risk factors for Hemolytic-uremic syndrome secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [3]
Overview
Hydration and supportive therapy can restrict complications.
Secondary Prevention
Effective measures for the secondary prevention of HUS include:[1][2][3]
- Supportive therapy and hydration
- Close observation for worsening clinical status
- Use of eculizumab in atypical HUS
- Avoidance of nephrotoxic medications
References
- ↑ Grisaru, Silviu (2014). "Management of hemolytic-uremic syndrome in children". International Journal of Nephrology and Renovascular Disease: 231. doi:10.2147/IJNRD.S41837. ISSN 1178-7058.
- ↑ Hoon Young Choi & Sung Kyu Ha (2013). "Potassium balances in maintenance hemodialysis". Electrolyte & blood pressure : E & BP. 11 (1): 9–16. doi:10.5049/EBP.2013.11.1.9. PMID 23946760. Unknown parameter
|month=ignored (help) - ↑ . doi:10.1007/s00467-018-4025-0 Share on FacebookShare on TwitterShare on Google+ Check
|doi=value (help). Missing or empty|title=(help)